ABL1 and Increased total leukocyte count: The significant increase in BCR-ABL under imatinib and laboratory tests revealed leukocytosis, which ranged from 147,720.00/mm3 (patient 1) to 328,720.00/mm3 (patient 2) and 55% to 85% of blasts (Table 2), reflecting the progression to blast crisis.